| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10408 | BAY1125976 Featured | BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. |
|
| DC22013 | BAY-1316957 Featured | BAY-1316957 (BAY 1316957) is a highly potent, selective, orally available human prostaglandin E2 receptor subtype 4 (hEP4-R) antagonist with IC50 of 15.3 nM. |
|
| DC11719 | BAY-1436032 | BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively. |
|
| DC20751 | BAY-1816032 Featured | BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM, displays excellent selectivity on a panel of 395 kinases. |
|
| DC23816 | BAY-293 racemate | BAY-293 racemate (BAY293 racemate) is a potent SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 50 nM, the R-enantiomer (BAY-293) is the active form with IC50 of 21 nM, while the BAY-293 is less active (IC50=2,340 nM).. |
|
| DC11006 | BAY-320 | BAY-320 (BAY320) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 680 nM. |
|
| DC10978 | BAY-3827 Featured | BAY-3827 (BAY3827) is a potent, selective inhibitor of AMPK as tool compound to evaluate the therapeutic potential of AMPK inhibition in MYC-dependent tumors; strongly inhibits Acetyl-CoA carboxylase (ACC) phosphorylation in COLO 320DM and IMR-32 cells, but fails to inhibit the proliferation of cells with dysregulated c-MYC or N-MYC. |
|
| DC22015 | BAY-386 | BAY-386 (BAY386) is a potent, specific and reversible PAR-1 antagonist with IC50 of 10 nM (HEK cell) and binding IC50 of 56 nM, without affinity for PAR-4 (IC50>10 uM). |
|
| DC11007 | BAY-524 | BAY-524 (BAY524) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 450 nM. |
|
| DC12088 | BAY-678 racemate | BAY-678 racemate is a chemical probe candidate for Human Neutrophil Elastase (HNE). |
|
| DC20749 | BAY-707 | BAY-707 is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM. |
|
| DC22016 | BAY-7598 | BAY-7598 (BAY7598) is a potent, selective MMP12 inhibitor.. |
|
| DC22017 | BAY-826 | BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM). |
|
| DC11915 | BAY-958 | BAY-958 (BAY958, LDC526) is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1. |
|
| DC10057 | Bayer-18 Featured | Bayer-18 is a selective TYK2 inhibitor, with an IC50 of 18.7nM on TYK2 as measured by TYK2 HTRF assays. |
|
| DC7854 | BAZ2-ICR | BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively). |
|
| DC12280 | BB-Cl-Amidine | BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor. |
|
| DC10058 | BBT594 | BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2. |
|
| DC20754 | BC-1215 Featured | BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL. |
|
| DC20755 | BC-1485 | BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination. |
|
| DC21401 | BC-21 | BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM. |
|
| DC20757 | BC-23 | BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM. |
|
| DC20758 | BCI-137 | BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM. |
|
| DC12446 | BCL6 inhibitor 14 | BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM.. |
|
| DC12447 | BCL6 PROTAC 15 | BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response. |
|
| DC20760 | BCL6-IN-8 | BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface. |
|
| DC20761 | BCM-599 | BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.. |
|
| DC23980 | BCX-1470 | BCX-1470 (BCX1470) is a serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM). |
|
| DC23499 | BD-1047 Featured | BD-1047 is a potent, selecitve Sigma 1 receptor (σ1) antagonist with Ki of 0.93 nM. |
|
| DC9709 | BDA-366 Featured | BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. |
|
